Most importantly, an early postnatal OXT treatment was demonstrated to rescue neonatal lethality and to prevent the appearance of social and learning deficits in adult Magel2-KO mice (Meziane et al., 2015; Bertoni et al., 2021), providing strong preclinical evidence for pilot studies of OXT treatment in PWS and SYS infants, such as that conducted in PWS babies showing encouraging positive results (Tauber et al., 2017). This evidence concerns the gene MAGEL2 and Prader-Willi syndrome.